Patent ID: 7105482

Claim:
A method of treating a subject having a lymphoid malignancy, comprising administering to the subject a therapeutically effective amount of a compound comprising the structure of Formula I, wherein A is a Met-AP2 inhibitory core; W is O or NR 2 ; R 1 and R 2 are each, independently, hydrogen or alkyl; X is alkylene or substituted alkylene; n is 0 or 1; R 3 and R 4 are each, independently, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; or R 3 and R 4 , together with the carbon atom to which they are attached, form a carbocyclic or heterocyclic group; or R 3 and R 4 together form an alkylene group; Z is —C(O)— or alkylene-C(O)—; and P is a peptide comprising from 1 to about 100 amino acid residues attached at its amino terminus to Z or a group OR 5 or N(R 6 )R 7 , wherein R 5 , R 6 and R 7 are each, independently, hydrogen, alkyl, substituted alkyl, azacycloalkyl or substituted azacycloalkyl; or R 6 and R 7 , together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocyclic ring structure; or Z is —O—, —NR 8 —, alkylene-O— or alkylene-NR 8 —, where R 8 is hydrogen or alkyl; and P is hydrogen, alkyl or a peptide consisting of from 1 to about 100 amino acid residues attached at its carboxy terminus to Z.